NSRX Latest Press Releases

-- September 29, 2026 --

Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron Globe Newswire 8:00 AM

-- September 14, 2026 --

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis Globe Newswire 8:00 AM

-- September 8, 2026 --

Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Globe Newswire 7:30 AM

-- August 19, 2026 --

Nasus Pharma Announces Transition of Chief Financial Officer Globe Newswire 7:00 AM

-- August 17, 2026 --

Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Globe Newswire 8:14 AM

-- July 28, 2026 --

Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth Globe Newswire 7:30 AM

-- June 26, 2026 --

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing Globe Newswire 8:35 AM

-- June 23, 2026 --

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th Globe Newswire 8:35 AM

-- June 22, 2026 --

Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum Globe Newswire 8:00 AM

-- June 9, 2026 --

Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes